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Abstract
Background: There are no universallymonitored outcomes relevant tomenwith advanced
prostate cancer, making it challenging to compare health outcomes between populations.
Objective: We sought to develop a standard set of outcomes relevant to men with
advanced prostate cancer to follow during routine clinical care.
Design, setting, and participants: The International Consortium for Health Outcomes
Measurement assembled a multidisciplinary working group to develop the set.
Outcome measurements and statistical analysis: We used a modiﬁed Delphi method to
achieve consensus regarding the outcomes, measures, and case mix factors included.
Results and limitations: The 25members of themultidisciplinary international working
group represented academic and nonacademic centers, registries, and patients. Recog-
nizing the heterogeneity of men with advanced prostate cancer, the group deﬁned the
scope as men with all stages of incurable prostate cancer (metastatic and biochemical
recurrence ineligible for further curative therapy).We deﬁned outcomes important to all
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We also identiﬁed patient-reported outcome measures (PROMs), such as degree of
urinary, bowel, and erectile dysfunction, mood symptoms, and pain control.
Conclusions: The international multidisciplinary group identiﬁed clinical data and
PROMs that serve as a basis for international health outcome comparisons and quali-
ty-of-care assessments. The set will be revised annually.
Patient summary: Our international group has recommended a standardized set of
patient-centered outcomes to be followed during routine care for allmenwith advanced
prostate cancer.
# 2015 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Prostate cancer is the most common noncutaneous malig-
nancy among men and causes the death of hundreds of
thousands of men each year worldwide [1]. The disease is
heterogeneous, and treatment varies at each stage of disease.
Although therapeutic guidelines have been developed by
variousorganizations,significantvariationinthecareactually
delivered in practice remains [2–4]. Evidence suggests that
standardization of clinical practice may reduce unnecessary
costs and improve quality of care, resulting in improved
health care value [5].
In the case of advanced prostate cancer, value must be
defined as it pertains to the consumer of care: the patient
[6]. For prostate cancer, this encompasses not only survival
but also a range of concerns regarding quality of life (QOL)
and complications that are too often unmeasured. Outside
of clinical trials and some registries and cohort studies,
few institutions collect outcomes beyond mortality. The
lack of meaningful measures for routine clinical practice
makes direct comparisons of health outcomes across patient
populations and between institutions challenging.
The International Consortium for Health Outcomes
Measurement (ICHOM) has developed a recommended
set of outcomes to be measured in a standardized way for
localized prostate cancer, and this set is currently being
monitored by a range of registries and provider organiza-
tions worldwide [7]. However, no such recommendation
exists for advanced prostate cancer. To address this, we
convened an international, multidisciplinary working group
to develop a single standardized set of outcome measures
pertinent to men with advanced prostate cancer for
monitoring during routine clinical practice and to allow
meaningful, systematic comparison of outcomes and quality
of care across health systems.
2. Materials and methods
An advanced prostate cancer working groupwas assembled by ICHOM, a
nonproﬁt organization that has developed standardized sets of pertinent
outcomes for multiple medical conditions. ICHOM is supported by an
array of organizations, including patient advocacy groups, specialty
societies, hospitals and health systems, governments, and private payers
(Supplementary material, Appendix 1). The diverse team of 25 experts
includes patient representatives, epidemiologists, palliative care spe-
cialists, nurse oncologists, medical oncologists, urologists, and radiation
oncologists from Europe, Australia, Canada and the USA. A smaller
project team (A.V.B., A.K.M., C.S., and D.P.) guided the efforts of the larger
group.The working group convened via six teleconferences between June
and December 2014, and proceeded through a structured process similar
to that described for the localized prostate cancer set and elsewhere
[7–10]. The project team performed a structured Medline (1990–2014)
literature review and prepared a proposal describing the ﬁndings
appropriate for discussion before each teleconference. The calls focused
on the following: (1) scope and outcome domains; (2) outcome
deﬁnitions and measures, including clinical data and patient-reported
outcome measures (PROMs); (3) case mix factors; and (4) case mix
measures. The Medline review retrieved randomized controlled trials
and cohort studies including men with advanced prostate cancer to
identify clinical outcomes and relevant measures of health-related QOL
(HR-QOL) (Supplementary material, Appendices 2–4). To assure inclu-
sion of all relevant studies, we also reviewed studies referenced in
identiﬁed articles, and asked working group experts to name other
sources that had not been identiﬁed. After each teleconference, we
circulated a survey and each member voted anonymously regarding
each topic. Amodiﬁed Delphi method requiring consensus by two-thirds
or more was required for inclusion of all proposed outcomes, case mix
factors, and measures (Supplementary material, Appendix 5). Members
of ICHOM maintained the data and conducted the surveys, but neither
ICHOM nor its funders inﬂuenced voting or manuscript preparation.
3. Results
3.1. Condition and treatment scope
This set was designed to cover a heterogeneous group of
men with prostate cancer who lack curative treatment
options. This includes men with M1 disease as defined by
American Joint Committee on Cancer staging, andmenwith
biochemical recurrence ineligible for further curative
therapy (Table 1) [11]. The working group acknowledged
that the population to which this set applies is heteroge-
neous, but defined the scope to include patients who may
have similar palliative goals of care. The set covers all forms
of systemic treatment for prostate cancer, including anti-
resorptive treatment for prevention of symptomatic skeletal
events (SSEs).
3.2. Outcome domains
After review of the literature and discussion, a list of 22
outcome domains was identified for discussion and voting
by the working group. Pain, overall survival, cause-specific
survival, and treatment complications were felt to be most
important to patients, with each receiving 95% support for
inclusion. Additional prioritized domains included are
noted in Table 2 and discussed below. Domains reviewed
in the literature but not receiving sufficient support for
Table 1 – Scope of the International Consortium for Health Outcomes Measurement advanced prostate cancer standard set
Men with M1 disease Deﬁned by American Joint Committee on Cancer
Men with biochemical
recurrence who failed
or are ineligible for
salvage therapy
Deﬁned as rising PSA after primary therapy
 Treated with primary RP: PSA 0.2 ng/ml followed by a second PSA 0.2 ng/ml a
 Treated with primary EBRT: rise in PSA of 2 ng/ml over the nadir PSA;b in practice,
this value is commonly conﬁrmed by a second measurement
PSA = prostate-speciﬁc antigen; RP = radical prostatectomy; EBRT = external beam radiation therapy.
a Based on the Americal Urological Association guidelines for Localized Prostate Cancer Update [12].
b Based on recommendations of the RTOG-ASTRO Phoenix Consensus Conference [13].
Table 2 – Summary of case mix variables for the International Consortium for Health Outcomes Measurement advanced prostate cancer
standard set
Category Population Measure Supporting information Timing Data source a
Treatment approach All patients ADT Update at least
annually
Clinical
All patients Hormonal therapy other
than ADT
Update at least
annually
Clinical
All patients Chemotherapy Update at least
annually
Clinical
All patients Immunotherapy Update at least
annually
Clinical
All patients Radiopharmaceuticals Update at least
annually
Clinical
All patients Radiation Update at least
annually
Clinical
All patients Bisphosphonates or denosumab Update at least
annually
Clinical
All patients Interventions for LP
complications
Update at least
annually
Clinical
Case mix variables
Demographic
factors
All patients Age Date of birth Baseline Clinical or PR
All patients Body mass index Height and weight Baseline Clinical or PR
All patients Ethnicity Determined by country Baseline PR
All patients Educational level Level of schooling completed b Baseline PR
All patients Marital status Relationship status Baseline PR
All patients Living status Living arrangements Baseline PR
Baseline clinical
factors
All patients Performance status ECOG/WHO scale for performance status Baseline Clinical
All patients Hb level at APC diagnosis Hb level at time of APC diagnosis Baseline Clinical
All patients Comorbidities Modiﬁed SCQ c Baseline PR
All patients Pain score Pain on scale of 0–10 Baseline PR
All patients Pain medication use Use of OTC or strong pain medicine Baseline PR
All patients Patient family history of PCa First-degree relative with PCa diagnosis Baseline PR
Baseline tumor
factors
All patients PSA level at APC diagnosis PSA value at time of APC diagnosis Baseline Clinical
All patients Pathologic/clinical stage Pathologic or clinical stage (AJCC [11]) Baseline Clinical
All patients Gleason score Gleason score at time of initial diagnosis Baseline Clinical
All patients Metastatic disease Radiographic or pathologic metastatic disease Baseline Clinical
Treatment factors All patients Prior radical prostatectomy Prior prostatectomy Baseline Clinical
All patients Receipt of radiation therapy Prior radiation to prostate Baseline Clinical
All patients Receipt of ADT Prior ADT Baseline Clinical
All patients Receipt of prior systemic
treatments
Prior systemic treatments other than ADT Baseline Clinical
All patients Receipt of bisphosphonates
or denosumab
Prior antiresorptive medication Baseline Clinical
ADT = androgen deprivation therapy; LP = local progression; PR = patient-reported; ECOG = Eastern Cooperative Oncology Group; WHO =World Health
Organization; Hb = hemoglobin; APC = advanced prostate cancer; SCQ = self-administered comorbidity questionnaire; PCa prostate cancer; AJCC = American
Joint Committee on Cancer; PSA = prostate-speciﬁc antigen.
a The data source reﬂects the way case mix variables and outcomes are collected. Clinical data include data abstraction and physician reports. PR data include
PR outcome measures and other relevant PR questions.
b Level of schooling deﬁned in each country according to the International Standard Classiﬁcation of Education.
c Have you ever been told by a doctor that you have any of the following? I have no other disease, heart disease (eg, angina, heart attack, or heart failure), high
blood pressure, leg pain when walking due to poor circulation, lung disease (eg, asthma, chronic bronchitis, or emphysema), diabetes, kidney disease, liver
disease, problems caused by stroke, disease of the nervous system (eg, Parkinson’s disease or multiple sclerosis), other cancer (within the last 5 yr), depression,
arthritis (select all that apply).
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index or weight gain or loss, among others. Following
prioritization, outcome domains were categorized into
three types: survival and disease control; degree of health;
and treatment complications.
3.3. Survival and disease control
Because prostate cancer is a terminal illness, overall
survival and prostate cancer–specific survival were easily
prioritized for inclusion in the set. The group recommended
that these should be collected via national death indices to
improve international comparability. Cancer control, in-
cluding metastasis-free survival and the development of
castration-resistant disease, was also prioritized as essen-
tial because of its effect on patient prognosis. In addition,
complications from local disease progression and SSE
occurrence were prioritized for tracking as they are
particularly burdensome to patients. Where possible, we
recommend continuous documenting of these disease
progression outcomes in structured forms throughout the
course of follow-up. Alternatively, annual chart abstraction
may be used.
3.4. Acute treatment complications
Although acute treatment complications received high
prioritization, there was considerable debate as to whether
their collection is feasible. Accurate comparability of
complication rates across institutions requires reliability of
data capture and use of common definitions, which may
require time-consuming audits for verification. We recom-
mend an adapted version of the US National Cancer Institute
Common Terminology Criteria for Adverse Events version
4 for tracking complication rates [14]. The adapted version
simplifies data collection by identifying only grade 3 or
4 complications and assigning a general category (cytope-
nias, infections, gastrointestinal toxicity, neuropathy, car-
diovascular events, or other). We recommend assessment of
complications occurring within 6mo of treatment initiation.
3.5. PROMs
HR-QOL is of utmost importance for men with advanced
prostate cancer. Because evidence suggests that physicians
often inaccurately estimate patient HR-QOL, PROMs have
been increasingly used to accurately describe a patient’s
own perceived result of care [15]. The working group
sought to identify a single, practical, validated PROM to
capture outcomes important tomenwith advanced prostate
cancer, but no single instrument adequately covered all the
prioritized domains (Supplementary material, Appendix 6).
Therefore, the working group decided to include both a
prostate cancer–specific questionnaire and an overall QOL
questionnaire. Although the group also wanted to include
measures of the quality of death and end-of-life care, no
well-validated PROMs currently exists for these domains,
and we advocate further research to develop a satisfactory
tool [16].The group recognized that it is important to assess
prostate cancer–specific QOL and complications from
previous local or hormonal therapy, and considered several
instruments according to their representation of questions
regarding sexual dysfunction and urinary, bowel, and
hormonal symptoms (Supplementary material, Appendix 6).
Patient representatives strongly stated that monitoring of
these outcomes is important, even among men with
advanced disease. We included the Expanded Prostate
Cancer Index Composite (EPIC) to assess these complica-
tions among men previously treated with local therapy or
hormonal therapy because it is a single instrument that
assesses the domains of sexual, urinary, hormonal, and
bowel function [17]. In addition, it was recommended in
the ICHOM localized prostate cancer standard set, allowing
a natural continuation of outcome measurement and
instrument familiarity for patients who experience recur-
rence after localized disease [7]. We recommend use of
the 26-item form of the EPIC because of its accumulated
psychometric evidence. However, we recognize that many
institutions will favor the shorter EPIC for clinical practice
(EPIC-CP), and consider it a valid alternative, albeit with
less accumulated evidence [18]. To improve the interpret-
ability of the sexual function domain of the EPIC, three
additional questions regarding libido and the use of sexual
medications or devices are also recommended (Table 2).
Tomeasure overall QOL, we evaluated both general tools,
including EQ-5D and SF-12, and cancer-specific tools,
including FACT-G and European Organization for Research
and Treatment of Cancer (EORTC) QLQ-C30 (Supplementary
material, Appendix 6). General tools failed to adequately
cover the prioritized domains and had less evidence
specifically describing use in the population with advanced
prostate cancer. Thus, these tools were eliminated. Of the
cancer-specific tools, we selected the EORTC QLQ-C30
instrument (Table 2) for several reasons [19]. First, there
is validation evidence for patients with advanced prostate
cancer. Second, there are many available validated transla-
tions that allow easy use internationally. Finally, there is
continued investment in the tool to improve its usability
over time. Efforts are ongoing to develop a computer
adaptive version of EORTC QLQ-C30, which will provide
similar domain coverage with higher sensitivity and lower
respondent burden [20].
We recommend evaluation of patient-reported health
status at the time of enrollment into the advanced prostate
cancer standardized set, at least 6 mo after initiation of
treatment, and annually until death (Fig. 1). Institutions
should ideally strive to measure PROMs as regularly as is
feasible to improve patient-provider communication and
real-time feedback on health status, although the group
recognizes that logistic challenges and potential respondent
burden will need to be balanced to make this successful.
3.6. Baseline characteristics
In a process similar to that described for outcome domains,
the working group developed a prioritized list of factors to
collect for adjustment of case mix (Table 3). Following
[(Fig._1)TD$FIG]
Fig. 1 – Selected sample timelines illustrating when particular outcomes and baseline factors should be collected for patients treated with different
modalities. Example 1, one treatment given. Example 2, multiple treatments needed after specific events or disease progression. These timelines are
intended to represent the outcome data collection points for possible treatment paths a patient could take, and do not advocate a particular
treatment approach. Of note, a majority of baseline factors should be collected at the time of initiation of the advanced prostate cancer set, although
several (eg, Gleason score, pathologic stage) are collected from information or treatment at the time of diagnosis. LPC = localized prostate cancer;
PROMs = patient-reported outcome measurements.
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demographic factors, clinical factors, tumor factors, and
previous treatments.
3.6.1. Demographics
The decision to include age as a factor that influences
patient outcomes was unanimous. Socioeconomic status
(SES) is also a key determinant of health outcomes in
oncology populations [21,22]. SES can be a difficult factor to
quantify for many reasons, including patient unwillingness
to share sensitive financial information and the lack of a
single measure that accurately reflects its complexity
[22]. The working group recommended assessment of SES
in terms of the highest level of education attained according
to the International Standard of Schooling Classification in
each participating country [23]. This measure is one that
patients generally feel comfortable reporting, and it can be
compared across countries [22]. Evidence suggests that
support outside the health care system, including marital
status, plays a significant role in prostate cancer outcomes
[24]. The working group recommended inclusion of both
marital status and living status (eg, I live with partner/
spouse/family/friends or I live alone).
3.6.2. Clinical factors
A patient’s baseline health status, including pain and the
burden of comorbid illness, is a key determinant of survival
outcomes and QOL in the oncology population [25]. Werecommend the collection of Eastern Cooperative Oncology
Group/World Health Organization performance status,
comorbidities, hemoglobin levels, pain scores and medica-
tion use, and family history of prostate cancer. The choice of
a comorbidity assessment tool was particularly challenging
because many exist but there is no gold standard. The
working group finally endorsed use of the modified self-
administered comorbidity questionnaire (SCQ) to collect
data for a list of comorbid diseases [26]. The SCQ predicts
functional outcomes as well as the medical record–based
Charlson comorbidity index does, and better predicts QOL
[27]. The SCQ can also be collected directly from patients,
thus avoiding the international inconsistency of adminis-
tratively coded data.
3.6.3. Tumor factors
Disease control and HR-QOL among men with prostate
cancer are highly dependent on tumor factors [21]. Clinical
(andpathologicwhere available) tumorgradeand stagewere
naturally included. Prostate-specific antigen level, extent of
metastatic disease, and Gleason scores at initial diagnosis
were added for adequate risk stratification (Table 3).
3.6.4. Treatment factors
Since most patients with advanced prostate cancer have
received treatments in the past, the working group decided
to include to include treatments given, such as radical
prostatectomy, radiation, androgen deprivation therapy
Table 3 – Summary of outcomes for the International Consortium for Health Outcomes Measurement advanced prostate cancer standard set
Outcome category Population Measure Supporting information Timing Data source a
ATCs Patients with ST Major ST
complications
Presence/absence of grade 3
including name of
adverse event while on therapy
and within 6 mo after TI
Update at least annually Clinical
Degree of
health
All patients Performance status ECOG/WHO scale for
performance status
Baseline; 3, 6, and 12 mo after TI;
ongoing annual tracking for life
Clinical
All patients Need for pain
medication
Use of OTC pain medicine or
strong pain medicine
Baseline; 3, 6, and 12 mo after TI;
ongoing annual tracking for life
PR
All patients Pain Tracked via EORTC QLQ-C30 Baseline; 3, 6, and 12 mo after TI;
ongoing annual tracking for life
PR
All patients Fatigue Tracked via EORTC QLQ-C30 Baseline; 3, 6, and 12 mo after TI;
ongoing annual tracking for life
PR
All patients Physical functioning Tracked via EORTC QLQ-C30 Baseline; 3, 6, and 12 mo after TI;
ongoing annual tracking for life
PR
All patients Emotional
functioning
Tracked via EORTC QLQ-C30 Baseline; 3, 6, and 12 mo after TI;
ongoing annual tracking for life
PR
All patients Urinary symptoms Tracked via EPIC-26 Baseline; 3, 6, and 12 mo after TI;
ongoing annual tracking for life
PR
All patients Bowel symptoms Tracked via EPIC-26 Baseline; 3, 6, and 12 mo after TI;
ongoing annual tracking for life
PR
All patients Hormonal symptoms Tracked via EPIC-26 Baseline; 3, 6, and 12 mo after TI;
ongoing annual tracking for life
PR
All patients Sexual dysfunction Tracked via EPIC-26 and
additional questions b
Baseline; 3, 6, and 12 mo after TI;
ongoing annual tracking for life
PR
Survival and
disease control
All patients Procedures
needed for LP
Receipt of speciﬁc procedures
because of LP c
1 yr after TI; ongoing annual
tracking for life
Clinical
All patients Symptomatic
skeletal event
Symptomatic fracture, cord
compression, or need
for bone surgery or radiation
1 yr after TI; ongoing annual
tracking for life
Clinical
Patients without
known metastasis
Development of
metastasis
Diagnosed with metastatic
disease
1 yr after TI; ongoing annual
tracking for life
Clinical
Patients who do
not yet have CRD
Development of CRD Diagnosed with CRD d 1 yr after TI; ongoing annual
tracking for life
Clinical
All patients Cause-speciﬁc
survival
Was death attributed to
prostate cancer on death
certiﬁcate
1 yr after TI; ongoing annual
tracking for life
Administrative
data (death registry)
All patients Overall survival Date of death 1 yr after TI; ongoing annual
tracking for life
Administrative
data (death registry)
ATCs = acute treatment complications; ST = systemic therapy; TI = treatment initiation; ECOG = Eastern Cooperative Oncology Group; WHO =World Health
Organization; PR = patient-reported; OTC = over the counter; EORTC = European Organization for Research and Treatment of Cancer; EPIC = Expanded Prostate
Cancer Index Composite; LP = local progression; CRD = castration-resistant disease.
a The data source reﬂects the way in which case mix variables and outcomes are collected. Clinical data include data abstraction and physician reports. PR
data include PR outcome measures (eg, EORTC QLQ-C30, EPIC-26) and other relevant PR questions.
b During the last 4 wks, to what extent were you interested in sex?: not at all, a little, quite a bit, very much; (2) Have you used any medications or devices to
aid or improve erections?: yes/no; and (3) For each of the following medications and devices, please indicate whether or not you have tried or currently use
it to improve your erections: Viagra or other pill, Muse (intraurethral alprostadil suppository), penile injection therapy (such as Caverject), vacuum erection
device (such as Erect-Aid), other (have not tried it; tried it, but was not helpful; it helped, but I am not using it now; it helped and I use it sometimes; it
helped and I use it always).
c Procedures include transurethral resection of the prostate, ureteral stent, percutaneous nephrostomy tube, suprapubic catheter placement, chronic Foley
catheter, and intermittent self-catheterization.
d Deﬁned as two successive increases in prostate-speciﬁc antigen at least 1 wk apart or the development or progression of radiographically proven
metastatic lesions in the setting of castrate levels of testosterone (<50 ng/ml).
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antiresorptive agents (Table 3).
3.7. Data collection
One of the ultimate goals of the ICHOMefforts is to provide a
single set of standard data that can be compared across
health care systems, countries, and patient populations. A
reference guide including sample questionnaires and a
data dictionary designed for each standard set created by
the ICHOM is an integral part of implementing the
measurement process, and will facilitate standardization
of data collection. The guide is free and is available on theICHOM website (www.ichom.org/medical-conditions/
advanced-prostate-cancer).
4. Discussion
Transparent measurement of outcomes and costs has the
potential to align patients, providers, and payers towards a
common goal of improving the value of care for patients
with advanced prostate cancer. Accurate assessments of
value require comparison of the same outcomes with the
same measures in a way that accounts for variability in
baseline health and prior therapies. Our working group,
deliberately comprising a diverse array of experts, reviewed
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felt mattered most to patients with advanced prostate
cancer, along with corresponding case mix factors. We
believe that the standardized measurement and reporting
of these outcomes from routine clinical care can lead to
accurate assessments of health care quality and practice
patterns in real-life populations, and could ultimately
accelerate the adoption of best practices.
The working group acknowledges that collection of this
standard set requires significant upfront investment in
information technology and/or data collection resources.
Organizations will certainly vary in their readiness to adopt
the set. Our intent is to facilitate adoption in a piecemeal
fashion, beginning with pilot institutions from the working
group. We anticipate significant learning from this early
testing phase that will allow the set to be refined as it is
rolled out further. To steer this refinement, a steering
committee of experts comprising balanced representation
from the working group will convene annually to consider
changes in the set over time.
Theworking group recognizes that inclusion of twoPROM
questionnaires comprising more than 50 questions repre-
sents a significant respondent burden. Ultimately, we felt
that the trade-off in domain coverage outweighed the
number of questions. A similar respondent burden has been
successfully managed for other conditions as long as the
questions answered remain salient for the patient [28]. In
time, we anticipate a lower respondent burden with the
transition to computer adaptive tests covering these same
domains.
Our process and recommendations have some limita-
tions that should be considered. First, although the
recommendations reflect a systematic assessment of the
literature and informed consensus among an international
team of experts, the suggested outcomes and measures
remain expert opinion. Other group efforts, such as
PROQOLID, serve a separate purpose in compiling PROM
instrument information to allow easy identification of an
instrument that measures the information of interest in a
given population, but does not incorporate expert opinion
into the process [29]. We sought to both identify outcomes
of interest and provide expert opinion to expedite large-
scale implementation as swiftly as possible. Second, new
PROMs may be developed that were not considered in our
review. The steering committee will review these devel-
opments annually and recommend whether to transition to
a new instrument for the same domain. Third, the standard
set recommended has not yet been proven in routine use.
For greater confidence in its usefulness and usability in
routine clinical practice, pilot testing will be needed.
Despite these concerns, we recommend this set as a
starting point towards routine collection of patient-
centered outcomes for men with advanced prostate cancer.
5. Conclusions
The advanced prostate cancer standard set was developed
by an international, multidisciplinary team to standardize
the measurement of outcomes deemed most important tomen with advanced prostate cancer. The working group
recommends measurement of these outcomes in routine
clinical practice to permit accurate assessments and
comparison of the value of care and to facilitate improve-
ment initiatives worldwide.
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